BLACKSTONE LIFE SCIENCES ADVISORS L.L.C.
BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. is a Series C+ fund in global writing $20M–$1B checks into healthcare-tech.
- Stages
- Series C+
- Sectors
- healthcare-tech
- Check size
- $20M–$1B
- Invests in
- global
- Founded
- 2017
- Assets under management
- $15B
Thesis
Blackstone Life Sciences Advisors L.L.C. (BXLS Advisors) specializes in life sciences investments, targeting late-stage clinical products, post-approval royalties, synthetic royalties, and structured credit related to life sciences. They aim to address unmet medical needs and improve patients' quality of life. They often partner with major biopharmaceutical companies through research and development collaborations. A significant portion of their funds is directed towards financing products in phase three development. BXLS provides early-stage, expansion, and later-stage financing, as well as PIPE opportunities. Blackstone Life Sciences VI (BLXS VI) closed at its hard cap of $6.3 billion in March 2026. BXLS investments have achieved an 86% approval success rate for phase 3 assets.
Common questions
Does BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. invest at the Series C+ stage?
Yes. BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. lists Series C+ among the stages it invests in.
What check size does BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. write?
BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. writes $20M–$1B checks.
Where does BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. invest?
BLACKSTONE LIFE SCIENCES ADVISORS L.L.C. invests in global.